Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an anti-tumor immune response
AACR Annual Meeting 2018
eFT508, A Potent and Highly Selective Inhibitor of MNK 1/2, Regulates T Cell Differentiation Promoting an Anti-tumor Immune Response
AACR Annual Meeting 2018
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of eFT508, a Selective, Orally Bioavailable Inhibitor of MNK1 and MNK2, in Patients with Hematological Malignancies
American Society of Hematology (ASH) Annual Meeting 2017
Preclinical Evaluation of eFT226, a Novel, Potent and Selective elF4A Inhibitor with Anti-tumor Activity in B-cell Malignancies
American Society of Hematology (ASH) Annual Meeting 2017
eFT508, A Potent and Highly Selective Inhibitor of MNK 1 and MNK2, is an Activator of Anti-Tumor Immune Response
2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
A Phase 1 Dose Escalation Study of eFT508, an Inhibitor of Mitogen-Activated Protein Kinase-Interacting Serine/Threonine Kinase-1 (MNK-1) and MNK-2 in Patients with Advanced Solid Tumors
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
eFT508, A Potent and Highly Selective Inhibitor of MNK 1/2, Regulates Immune Checkpoint and Cytokine Expression Promoting Anti-tumor Immunity
American Association for Cancer Research (AACR) Annual Meeting 2017
eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)
American Society of Hematology (ASH) Annual Meeting 2015